Mabpharm Limited
HKEX:2181.HK
0.295 (HKD) • At close November 14, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 87.161 | 55.918 | 82.882 | 0 | 14.074 | 23.927 | 4.69 |
| Cost of Revenue
| 11.923 | 15.375 | 16.777 | 0 | 0 | 0 | 0 |
| Gross Profit
| 75.238 | 40.543 | 66.105 | 0 | 14.074 | 23.927 | 4.69 |
| Gross Profit Ratio
| 0.863 | 0.725 | 0.798 | 0 | 1 | 1 | 1 |
| Reseach & Development Expenses
| 123.211 | 147.906 | 263.572 | 120.418 | 134.189 | 88.983 | 21.632 |
| General & Administrative Expenses
| 21.018 | 21.969 | 21.291 | 18.456 | 90.479 | 34.365 | 4.867 |
| Selling & Marketing Expenses
| 48.925 | 28.213 | 9.423 | 0 | 0 | 0 | 0 |
| SG&A
| 69.943 | 50.182 | 30.714 | 18.456 | 90.479 | 34.365 | 4.867 |
| Other Expenses
| 0 | 41.668 | 56.477 | 24.56 | -14.074 | 1.726 | 0.326 |
| Operating Expenses
| 75.238 | 239.756 | 350.763 | 163.434 | 210.594 | 147.543 | 42.475 |
| Operating Income
| -199.693 | -203.83 | -289.268 | -180.69 | -194.834 | -148.112 | -44.378 |
| Operating Income Ratio
| -2.291 | -3.645 | -3.49 | 0 | -13.844 | -6.19 | -9.462 |
| Total Other Income Expenses Net
| -9.663 | -6.989 | -2.476 | -3.942 | -7.695 | -45.409 | -3.328 |
| Income Before Tax
| -209.356 | -210.819 | -291.744 | -184.632 | -202.529 | -152.593 | -47.706 |
| Income Before Tax Ratio
| -2.402 | -3.77 | -3.52 | 0 | -14.39 | -6.377 | -10.172 |
| Income Tax Expense
| 0 | -0.199 | 2.476 | 3.942 | 7.695 | -2.834 | -16.642 |
| Net Income
| -209.356 | -210.62 | -294.22 | -188.574 | -210.224 | -124.883 | -31.064 |
| Net Income Ratio
| -2.402 | -3.767 | -3.55 | 0 | -14.937 | -5.219 | -6.623 |
| EPS
| -0.051 | -0.051 | -0.071 | -0.046 | -0.055 | -0.03 | -0.008 |
| EPS Diluted
| -0.051 | -0.051 | -0.071 | -0.046 | -0.055 | -0.03 | -0.008 |
| EBITDA
| -139.083 | -152.082 | -245.464 | -169.933 | -172.636 | -107.975 | -34.298 |
| EBITDA Ratio
| -1.596 | -2.723 | -2.961 | 0 | -12.266 | -5.701 | -7.313 |